Beam Therapeutics(NASDAQ) BEAM

Beam Therapeutics NASDAQ:BEAM helps people with serious genetic diseases by fixing errors in DNA. These treatments repair tiny mistakes in a person's genetic code to treat blood and liver conditions. The company uses a precise technology called base editing to improve patient health.

What Is Beam Building?

• Hematology Programs: Treatments for blood disorders like sickle cell disease that edit a patient's own cells outside the body.
• Genetic Disease Programs: Medicines delivered directly to the liver to treat inherited conditions like Alpha-1 antitrypsin deficiency.
• Base Editing Platform: Technology that changes single DNA letters without cutting through the entire genetic strand.
• Manufacturing Facility: A 100,000 square foot site in North Carolina built to produce these genetic medicines.

Partnerships and Progress

• Partnered with Eli Lilly in 2023, receiving a $200 million payment for rights to cardiovascular disease targets.
• Received $255.1 million in cash in 2025 after Bristol Myers Squibb acquired Beam's partner, Orbital Therapeutics.
• Secured a credit facility in February 2026 for up to $500 million to fund clinical and commercial development.
• Achieved a $25 million milestone payment from Eli Lilly during the six-month period ended June 30, 2026.

Precision Without the Breaks

Beam uses base editing to make precise changes to DNA without creating double-stranded breaks. This method uses a chemical reaction to target specific genetic sequences more predictably than traditional methods.

Performance in the Clinic

• License and collaboration revenue rose to $32.2 million for the six months ended June 30, 2026.
• Net loss was $217.0 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $1.2 billion as of June 30, 2026.
• Research and development expenses were $199.6 million during the first half of 2026.

The Genetic Path Forward

Beam has transitioned from a research-focused startup to a clinical-stage firm with multiple human trials. It continues to leverage its proprietary platform through pharmaceutical partnerships and internal manufacturing.